Overcoming endocrine resistance in breast cancer-are signal transduction inhibitors the answer?

被引：45

作者：

Bedard, Philippe L. ^{[1
]}

Freedman, Orit C. ^{[1
]}

Howell, Anthony ^{[2
]}

Clemons, Mark ^{[1
]}

机构：

[1] Princess Margaret Hosp, Div Med Oncol, Toronto, ON M6C 3A5, Canada

[2] Christie Hosp, Div Med Oncol, Manchester, Lancs, England

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2008年 / 108卷 / 03期

关键词：

endocrine resistance; signal transduction inhibitor; estrogen receptor;

D O I：

10.1007/s10549-007-9606-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endocrine therapy is probably the most important systemic therapy for hormone receptor positive breast cancer. Hormonal manipulation was the first targeted treatment employed in breast cancer therapy even before the role of the estrogen (ER) and progesterone receptors (PR) had been elucidated. Unfortunately, a substantial proportion of patients, despite being ER and/or PR positive, are either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Signaling through complex growth factor receptor pathways, which activate the ER are emerging as important causes of endocrine resistance. Targeted therapies, such as signal transduction inhibitors (STIs), are being explored as agents to be able to potentially overcome this crosstalk and thus, resistance to hormone treatment. This article reviews the biology of the ER, the proposed mechanisms of endocrine resistance, and ongoing clinical trials with STIs in combination with hormonal manipulation as a means to overcome endocrine resistance.

引用

页码：307 / 317

页数：11

共 82 条

[1] Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone [J].

Achuthan, R ;

Bell, SM ;

Roberts, P ;

Leek, JP ;

Horgan, K ;

Markham, AF ;

MacLennan, KA ;

Speirs, V .

CANCER GENETICS AND CYTOGENETICS, 2001, 130 (02) :166-172

[2] Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance [J].

Arpino, G ;

Weiss, H ;

Lee, AV ;

Schiff, R ;

De Placido, S ;

Osborne, CK ;

Elledge, RM .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1254-1261

[3] Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women [J].

Balleine, RL ;

Earl, MJ ;

Greenberg, ML ;

Clarke, CL .

BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1564-1571

[4]

Bamberger AM, 2000, HORM RES, V54, P32

[5] Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J].

Bardou, VJ ;

Arpino, G ;

Elledge, RM ;

Osborne, CK ;

Clark, GM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1973-1979

[6] Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc [J].

Barletta, F ;

Wong, CW ;

McNally, C ;

Komm, BS ;

Katzenellenbogen, B ;

Cheskis, BJ .

MOLECULAR ENDOCRINOLOGY, 2004, 18 (05) :1096-1108

[7] Long-term exposure to tamoxifen induces hypersensitivity to estradiol [J].

Berstein, LM ;

Wang, JP ;

Zheng, H ;

Yue, W ;

Conaway, M ;

Santen, RJ .

CLINICAL CANCER RESEARCH, 2004, 10 (04) :1530-1534

[8] Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes:: Data from the Italian tamoxifen trial [J].

Bonanni, Bernardo ;

Macis, Debora ;

Maisonneuve, Patrick ;

Johansson, Harriet A. ;

Gucciardo, Giacomo ;

Oliviero, Pasquale ;

Travaglini, Roberto ;

Muraca, Maria G. ;

Rotmensz, Nicole ;

Veronesi, Umberto ;

Decensi, Andrea U. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3708-3709

[9]

CARPENTER JT, 2005, J CLIN ONCOL S, V23, P564

[10]

CHOW LW, 2006, ANN ONCOL S9, V17

← 1 2 3 4 5 6 7 8 9 →